Highbridge Capital Management’s Haemonetics HAE Stock Holding History

Highbridge Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-18,508	Closed	-$1.66M	–	649
2018 Q2	$1.66M	Buy	+18,508	New	+$1.56M	0.03%	404
2017 Q4	–	Sell	-9,895	Closed	-$444K	–	1768
2017 Q3	$444K	Sell	9,895 -3,559	-26%	-$148K	0.01%	998
2017 Q2	$532K	Buy	+13,454	New	+$553K	0.01%	739
2016 Q4	–	Sell	-61,001	Closed	-$2.21M	–	1384
2016 Q3	$2.21M	Sell	61,001 -159,466	-72%	-$5.47M	0.04%	413
2016 Q2	$6.39M	Buy	220,467 +157,703	+251%	+$4.77M	0.1%	221
2016 Q1	$2.19M	Buy	62,764 +8,204	+15%	+$265K	0.04%	486
2015 Q4	$1.76M	Buy	+54,560	New	+$1.77M	0.03%	562
2014 Q2	–	Sell	-103,370	Closed	-$3.37M	–	1155
2014 Q1	$3.37M	Buy	+103,370	New	+$3.95M	0.04%	308

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Highbridge Capital Management's HAE Position: Q3 2018 in Review

Highbridge Capital Management sold out of Haemonetics (HAE) in Q3 2018, closing a stake of 18,508 shares — an estimated $1.66M sold.

Highbridge Capital Management first reported a position in HAE in Q1 2014 and held it in 8 quarters. The position peaked at $6.39M in Q2 2016. 292 funds tracked by Wall St. Rank hold HAE as of Q3 2018.

Highbridge Capital Management reported no remaining Haemonetics position as of Q3 2018 after selling out during the quarter.
Highbridge Capital Management sold 18,508 Haemonetics shares in Q3 2018, an estimated $1.66M.
Highbridge Capital Management first reported a position in Haemonetics in Q1 2014 and held it in 8 quarters.
Highbridge Capital Management's Haemonetics position peaked at $6.39M in Q2 2016.
292 funds tracked by Wall St. Rank held Haemonetics as of Q3 2018.

Based on Highbridge Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.